Research Article
High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling
Table 2
Correlation between clinical characteristics and expression of VSTM2L in GSE87211 about preoperative chemoradiotherapy of rectal cancer (total
).
| Characteristics | | VSTM2L expression (%) | value | High () | Low () |
| Age | >60 | 40 | 74 | 0.144 | <60 | 33 | 39 |
| Gender | Male | 50 | 79 | 0.838 | Female | 23 | 34 |
| Kras mutation | Wild type | 44 | 61 | 0.398 | Mutation type | 29 | 52 |
| Preoperative treatment | 5-FU+RT | 38 | 61 | 0.233 | 5-FU+oxaliplatin+RT | 35 | 48 | FU+oxaliplatin+cetuximab+RT | 0 | 4 |
| Invasion depth before pCRT | T2 | 1 | 4 | 0.166 | T3 | 65 | 105 | T4 | 7 | 4 |
| Invasion depth after pCRT | T0 | 10 | 22 | 0.842 | T1 | 7 | 13 | T2 | 18 | 24 | T3 | 34 | 48 | T4 | 4 | 6 |
| LN metastasis before pCRT | N0 | 29 | 33 | 0.137 | N1 | 44 | 80 |
| LN metastasis after pCRT | N0 | 47 | 86 | 0.217 | N1 | 20 | 20 | N2 | 6 | 7 |
| Metastasis before pCRT | M0 | 68 | 108 | 0.474 | M1 | 5 | 5 |
| Metastasis after pCRT | M0 | 66 | 107 | 0.264 | M1 | 7 | 6 |
| ypTNM stage before pCRT | I+II | 29 | 31 | 0.080 | III+IV | 44 | 82 |
| TNM stage after pCRT | I+II | 46 | 82 | 0.170 | III+IV | 27 | 31 |
| Tumor downstage after pCRT | No | 33 | 37 | 0.087 | Yes | 40 | 76 |
| Tumor regression after pCRT | No | 32 | 32 | 0.030 | Yes | 41 | 81 |
| Recurrence after surgery | No | 51 | 89 | 0.170 | Yes | 22 | 24 |
|
|
was considered significant. |